Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435690 | 1.00 | ALDH1A1 (0.50) | ALDH1A1POLBKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL19728987 | 0.79 | PIK3CD (0.43) | ALDH1A1POLBKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL1716472 | 0.78 | ALDH1A1 (0.44) | ALDH1A1POLBKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL120994 | 0.78 | ALDH1A1 (0.56) | ALDH1A1POLBKDM4ESMN1; SMN2PLAU | |
| SCHEMBL30762204 | 0.78 | ALDH1A1 (0.44) | ALDH1A1POLBKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL29414916 | 0.78 | ALDH1A1 (0.56) | ALDH1A1POLBKDM4ESMN1; SMN2PLAU | |
| SCHEMBL30144074 | 0.77 | AGBL2 (0.47) | ALDH1A1POLBKDM4ESMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL3038475 | 0.77 | ALDH1A1 (0.43) | ALDH1A1POLBKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL30062543 | 0.77 | ALDH1A1 (0.46) | ALDH1A1POLBKDM4ESMN1; SMN2PLAU | |
| SCHEMBL31310688 | 0.77 | PIK3CD (0.50) | ALDH1A1POLBKDM4ESMN1; SMN2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118325407-A | Wear-resistant quick-drying water-based paint and preparation method thereof | 龙南县彩艺装饰材料厂 | 2024-07-12 | — | — | CN | claimed |
| WO-2026106929-A1 | DIHYDROQUINAZOLINES USEFUL AS CYTOMEGALOVIRUS ANTIVIRAL AGENTS | ASSEMBLY BIOSCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4646263-A1 | SPRK1 INHIBITORS AND METHODS OF USE | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-20250206755-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-06-26 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024155864-A1 | SPRK1 INHIBITORS AND METHODS OF USE | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-25 | — | — | WO | disclosed |
| CN-118325407-A | Wear-resistant quick-drying water-based paint and preparation method thereof | 龙南县彩艺装饰材料厂 | 2024-07-12 | — | — | CN | disclosed |
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| EP-1984345-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| EP-0178260-B1 | PROCESS FOR THE PREPARATION OF FLUORINATED PYRIDINE DERIVATIVES | CIBA-GEIGY AG (CH) | 1990-05-16 | — | — | EP | disclosed |
| US-4831148-A | DIAZOTISING A 3-AMINO-2-HALOPYRIDINE IN PRESENCE OF HYDROGEN FLUORIDE | CIBA-GEIGY CORPORATION (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0178260-A2 | Process for the preparation of fluorinated pyridine derivatives | CIBA-GEIGY AG (CH) | 1986-04-16 | — | — | EP | disclosed |
| US-4393212-A | ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1983-07-12 | — | — | US | disclosed |
| EP-0031218-B1 | A 2-AMINO-TRIFLUOROMETHYL-HALOGENOPYRIDINE COMPOUND AND A PROCESS FOR PRODUCING THE SAME | ISHIHARA SANGYO KAISHA LTD. (JP) | 1983-05-11 | — | — | EP | disclosed |
| US-4294969-A | COUPLING N-BROMOSUCCINIMIDE AND A 2-BROMOPYRIDINE | MERCK & CO., INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4279913-A | ANTIARRYTHMIA, HYPOTENSIVE | MERCK & CO., INC. (US) | 1981-07-21 | — | — | US | disclosed |
| EP-0003278-A1 | Polysubstituted-2-(3-loweralkylamino-2-R0-propoxy)pyridines, process for preparing the same, and pharmaceutical compositions containing the same | MERCK & CO. INC. (US) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | ALDH1A1 1513/4885POLB 2820/4885KDM4E 3831/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | ALDH1A1 1513/4885POLB 2820/4885KDM4E 3831/4885 |
| US-20250206755-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | ALDH1A1 1945/4885POLB 2530/4885KDM4E 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.